Catalyst
Slingshot members are tracking this event:
PDUFA priority review February 6, 2016 for sNDA of ALYDECO (ivacaftor) for Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 05, 2016
Occurred Source:
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=953584
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pdufa, Priority Review, Snda, Alydeco, Ivacaftor, Cystic Fibrosis
